RxDoctor Payments Data

Munther Hijazin, MD

Neurology · Downey, CANPI 1952319253

Payments from drug & device makers

$42,810in general payments, 2019–2025

Across 3,383 payments — averaging $12.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • UCB, Inc.$4K
  • Livanova USA, Inc.$3K
  • Teva Pharmaceuticals USA, Inc.$3K
  • Novartis$3K
  • SK Life Science, Inc.$2K
  • plus $23K from 54 others

What the payments were for

  • Speaking & faculty fees$8162%
  • Food & beverage$41,11696%
  • Education$8782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)493$4,371
UCB, Inc.250$4,114
Livanova USA, Inc.521$3,491
Teva Pharmaceuticals USA, Inc.251$3,222
Novartis198$2,544
SK Life Science, Inc.201$2,306
EMD Serono, Inc.144$1,749
Biogen98$1,601
Neurocrine Biosciences, Inc.83$1,429
Sunovion Pharmaceuticals Inc.119$1,343
AstraZeneca(2 entities)64$1,343
Eisai Inc.106$1,318
Amgen56$1,081
Amneal Pharmaceuticals LLC46$1,048
Acorda Therapeutics, Inc78$1,027
Sumitomo Pharma America, Inc.95$908
Neurelis, Inc.64$830
Sanofi42$763
Kyowa Kirin, Inc.38$755
Lilly USA, LLC61$733
Pfizer28$619
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)42$587
MDD US Operations, LLC21$421
Aquestive Therapeutics, Inc.24$362
Acadia Pharmaceuticals Inc29$345
Catalyst Pharmaceuticals, Inc.15$311
Argenx US, Inc.13$307
Bristol Myers Squibb13$267
Boston Scientific8$263
Biohaven Pharmaceutical Holding Company Ltd.15$252
Vanda Pharmaceuticals Inc.9$242
Genentech USA, Inc.12$239
Scilex Pharmaceuticals Inc.12$234
Otsuka America Pharmaceutical, Inc.16$229
Adamas Pharmaceuticals, Inc.15$221
Lundbeck LLC10$193
Avanir Pharmaceuticals, Inc.10$191
Johnson & Johnson10$189
Corium, LLC8$172
Greenwich Biosciences, Inc.6$157
Abbott5$136
Aucta Pharmaceuticals, Inc.8$135
Biohaven Pharmaceuticals, Inc.8$133
Banner Life Sciences, LLC6$129
E.r. Squibb & Sons, L.L.C.4$72
Tanabe Pharma America, Inc.3$62
Impel Pharmaceuticals Inc.3$52
Supernus Pharmaceuticals, Inc.2$32
Mallinckrodt Hospital Products Inc.1$31
Takeda Pharmaceuticals U.S.A., Inc.6$27
Jazz Pharmaceuticals Inc.1$25
Avion Pharmaceuticals1$25
Sanofi-aventis U.S. LLC1$22
Forte Bio-pharma LLC1$20
Mallinckrodt Enterprises LLC1$17
Medtronic1$16
Idorsia Pharmaceuticals US Inc1$16
Arbor Pharmaceuticals, Inc.1$15
Almatica Pharma LLC1$14
Azurity Pharmaceuticals, Inc.1$14

How this compares

$42,810 in reported general payments places this provider in the 85th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$577,920
Medicare patients
736
Services billed
5,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl83$113,709
BetaseronInterferon Beta-1b11$104,860
Kesimpta PenOfatumumab12$101,514
AptiomEslicarbazepine Acetate52$85,370
BriviactBrivaracetam63$80,738
Rufinamide29$49,664
FycompaPerampanel47$46,369
RexultiBrexpiprazole26$37,409
NamzaricMemantine Hcl/Donepezil Hcl54$37,263
Memantine Hcl2,260$36,943
Levetiracetam873$28,357
GocovriAmantadine Hcl15$25,036
Lacosamide185$18,803
RytaryCarbidopa/Levodopa39$17,544
Entacapone90$16,519

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Namzaric$4,371$150,972137 claims
UCB, Inc.Briviact, Nayzilam$4,114$90,58177 claims
Sunovion Pharmaceuticals Inc.Aptiom$1,343$85,37052 claims
Eisai Inc.Fycompa$1,318$46,36947 claims
Otsuka America Pharmaceutical, Inc.Rexulti$229$37,40926 claims
MDD US Operations, LLCGocovri$421$25,03615 claims
Amneal Pharmaceuticals LLCRytary$1,048$17,54439 claims
Neurelis, Inc.Valtoco$830$15,00916 claims
PfizerDilantin$619$2,75912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,996 neurology providers in California.

Other neurology in Downey

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →